Randomized, Double-blind, Placebo-controlled, Single-centre, Phase I Safety Study of Intradermal Injections of RCS-01 in Male and Female Subjects (50 to 65 Years Old)

Trial Profile

Randomized, Double-blind, Placebo-controlled, Single-centre, Phase I Safety Study of Intradermal Injections of RCS-01 in Male and Female Subjects (50 to 65 Years Old)

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Autologous-non-bulbar-dermal-sheath-fibroblast-therapy-RepliCel-Life-Sciences (Primary)
  • Indications Photosensitivity; Skin aging
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors RepliCel Life Sciences
  • Most Recent Events

    • 10 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2017 Results published in a RepliCel Life Sciences media release.
    • 04 Apr 2017 Planned End Date changed from 1 Feb 2018 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top